Instituto Nacional del Cáncer "Cancer Moonshot Biobank"
Protocolo de Investigación del Biobanco Moonshot del Cáncer
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
- Neoplasia Sólida Maligna
- Melanoma
- Leucemia mieloide aguda
- Mieloma múltiple
- Cáncer de mama anatómico en estadio III AJCC v8
- Cáncer de mama anatómico en estadio IV AJCC v8
- Carcinoma de las trompas de Falopio
- Carcinoma gástrico
- Carcinoma de células no pequeñas de pulmón
- Cáncer de pulmón en estadio III AJCC v8
- Cáncer de pulmón en estadio IV AJCC v8
- Carcinoma de próstata metastásico
- Carcinoma de ovario
- Carcinoma de esófago
- Carcinoma de mama invasivo
- Cáncer de próstata en estadio IVB AJCC v8
- Cáncer gástrico en estadio clínico IV AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio clínico IV AJCC v8
- Carcinoma de mama triple negativo
- Cáncer colorrectal en estadio IV AJCC v8
- Carcinoma Peritoneal Primario
- Adenocarcinoma de esófago en estadio clínico IV AJCC v8
- Adenocarcinoma seroso de alto grado de ovario
- Cáncer de trompa de Falopio en estadio III AJCC v8
- Cáncer de ovario en estadio III AJCC v8
- Cáncer de trompa de Falopio en estadio IV AJCC v8
- Cáncer de ovario en estadio IV AJCC v8
- Carcinoma de mama con receptor hormonal positivo
- Carcinoma de células pequeñas de pulmón
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVE:
I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.
SECONDARY OBJECTIVES:
I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.
II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.
III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.
IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.
V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.
VI. To provide residual biospecimens and associated data from the project to the cancer research community.
OUTLINE:
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Daphne, Alabama, Estados Unidos, 36526
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Estados Unidos, 36532
- Thomas Hospital
-
Mobile, Alabama, Estados Unidos, 36607
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Estados Unidos, 36571
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Kingman, Arizona, Estados Unidos, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Fort Smith, Arkansas, Estados Unidos, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Arroyo Grande, California, Estados Unidos, 93420
- PCR Oncology
-
Bakersfield, California, Estados Unidos, 93301
- AIS Cancer Center at San Joaquin Community Hospital
-
Loma Linda, California, Estados Unidos, 92357
- Veterans Affairs Loma Linda Healthcare System
-
Salinas, California, Estados Unidos, 93901
- Salinas Valley Memorial
-
-
Colorado
-
Brighton, Colorado, Estados Unidos, 80601
- Intermountain Health Platte Valley Hospital
-
Denver, Colorado, Estados Unidos, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Golden, Colorado, Estados Unidos, 80401
- Lutheran Hospital - Cancer Centers of Colorado
-
Grand Junction, Colorado, Estados Unidos, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Lafayette, Colorado, Estados Unidos, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06102
- Hartford Hospital
-
-
Delaware
-
Dover, Delaware, Estados Unidos, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Estados Unidos, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33486
- Boca Raton Regional Hospital
-
Deerfield Beach, Florida, Estados Unidos, 33064
- Broward Health North
-
Fort Lauderdale, Florida, Estados Unidos, 33316
- Broward Health Medical Center
-
Tampa, Florida, Estados Unidos, 33606
- Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- Northside Hospital
-
Savannah, Georgia, Estados Unidos, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Illinois
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Chicago, Illinois, Estados Unidos, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Estados Unidos, 60625
- Swedish Covenant Hospital
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Evanston, Illinois, Estados Unidos, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Estados Unidos, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Estados Unidos, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Estados Unidos, 62864
- SSM Health Good Samaritan
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Washington, Illinois, Estados Unidos, 61571
- Illinois CancerCare - Washington
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Estados Unidos, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Cedar Rapids, Iowa, Estados Unidos, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Estados Unidos, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Our Lady of the Lake Physician Group
-
New Orleans, Louisiana, Estados Unidos, 70118
- Children's Hospital New Orleans
-
New Orleans, Louisiana, Estados Unidos, 70112
- University Medical Center New Orleans
-
Shreveport, Louisiana, Estados Unidos, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Estados Unidos, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Estados Unidos, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Estados Unidos, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brunswick, Maine, Estados Unidos, 04011
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Brunswick, Maine, Estados Unidos, 04011
- Mid Coast Hospital
-
Damariscotta, Maine, Estados Unidos, 04543
- MaineHealth LincolnHealth Hospital
-
Farmington, Maine, Estados Unidos, 04938
- MaineHealth Franklin Hospital
-
Lewiston, Maine, Estados Unidos, 04240
- Saint Mary's Regional Medical Center
-
Norway, Maine, Estados Unidos, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Estados Unidos, 04102
- Maine Medical Partners Surgical Care
-
Portland, Maine, Estados Unidos, 04102
- MMP Surgical Care Casco Bay
-
Portland, Maine, Estados Unidos, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Estados Unidos, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Estados Unidos, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Estados Unidos, 04074
- Maine Children's Cancer Program
-
Scarborough, Maine, Estados Unidos, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Estados Unidos, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
South Portland, Maine, Estados Unidos, 04106
- MaineHealth Urology - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Estados Unidos, 48118
- Chelsea Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Iron Mountain, Michigan, Estados Unidos, 49801
- Dickinson County Healthcare System
-
Livonia, Michigan, Estados Unidos, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
-
Missouri
-
Ballwin, Missouri, Estados Unidos, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Joplin, Missouri, Estados Unidos, 64804
- Freeman Health System
-
Joplin, Missouri, Estados Unidos, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Estados Unidos, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Estados Unidos, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Estados Unidos, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Estados Unidos, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Estados Unidos, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Estados Unidos, 63128
- Mercy Hospital South
-
Washington, Missouri, Estados Unidos, 63090
- Mercy Hospital Washington
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- Saint Vincent Frontier Cancer Center
-
Butte, Montana, Estados Unidos, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
-
Nevada
-
Carson City, Nevada, Estados Unidos, 89703
- Carson Tahoe Regional Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Estados Unidos, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Estados Unidos, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Estados Unidos, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Hampshire
-
Nashua, New Hampshire, Estados Unidos, 03060
- Saint Joseph Hospital
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07960
- Morristown Medical Center
-
Newton, New Jersey, Estados Unidos, 07860
- Newton Medical Center
-
Pompton, New Jersey, Estados Unidos, 07444
- Chilton Medical Center
-
Summit, New Jersey, Estados Unidos, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Estados Unidos, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina University
-
Greenville, North Carolina, Estados Unidos, 27834
- ECU Health Medical Center
-
Kernersville, North Carolina, Estados Unidos, 27284
- Novant Health Cancer Institute - Kernersville
-
Kinston, North Carolina, Estados Unidos, 28501
- ECU Health Oncology Kinston
-
Mount Airy, North Carolina, Estados Unidos, 27030
- Novant Health Cancer Institute - Mount Airy
-
Pinehurst, North Carolina, Estados Unidos, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Thomasville, North Carolina, Estados Unidos, 27360
- Novant Health Cancer Institute - Thomasville
-
Washington, North Carolina, Estados Unidos, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Novant Health Forsyth Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Mercy Hospital Oklahoma City
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02908
- Roger Williams Medical Center
-
-
South Carolina
-
Columbia, South Carolina, Estados Unidos, 29203
- Prisma Health Richland Hospital
-
Columbia, South Carolina, Estados Unidos, 29220
- Prisma Health Baptist Hospital
-
Gaffney, South Carolina, Estados Unidos, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Greenville Memorial Hospital
-
Greer, South Carolina, Estados Unidos, 29651
- Gibbs Cancer Center-Pelham
-
Spartanburg, South Carolina, Estados Unidos, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Estados Unidos, 29379
- SMC Center for Hematology Oncology Union
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- Audie L Murphy VA Hospital
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24501
- Centra Alan B Pearson Regional Cancer Center
-
Richmond, Virginia, Estados Unidos, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Renton, Washington, Estados Unidos, 98055
- Valley Medical Center
-
Yakima, Washington, Estados Unidos, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Estados Unidos, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Saint Luke's Medical Center
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
-
-
-
San Juan, Puerto Rico, 00917
- San Juan Community Oncology Group
-
San Juan, Puerto Rico, 00927
- Centro Comprensivo de Cancer de UPR
-
San Juan, Puerto Rico, 00936
- San Juan City Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients undergoing treatment for cancer types with commercially available therapies.
Descripción
Inclusion Criteria:
-
Is consistent with OR has been diagnosed with one of the following:
-
Colorectal cancer: stage IV
-
Non-small cell or small cell lung cancer: stage III/IV
-
Prostate cancer: metastatic prostate cancer
-
Gastric cancer, not otherwise specified (NOS): stage IV
-
Esophageal cancer, NOS: stage IV
-
Adenocarcinoma of gastroesophageal junction: stage IV
-
High grade serous ovarian cancer: stage III/IV
-
Invasive breast carcinoma: stage III/IV
-
Melanoma: stage III/IV
-
Acute myeloid leukemia
-
Multiple myeloma
-
For the purposes of this study,
- Re-staging is allowed
- Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
-
-
-
Patient should fit in one of the following four clinical scenarios (a-d)
- Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
- Scheduled to begin treatment with a new regimen of standard of care therapy OR
- Currently progressing on a regimen of standard of care therapy OR
- Currently being treated with a regimen standard of care therapy, without evidence of progression
-
Requirements for fresh tissue biospecimen collections at enrollment:
-
For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment
-
For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy
-
For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure
-
For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR
-
The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling
- Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
-
-
-
Requirements for archival tissue:
-
For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE
-
For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED
-
Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:
- Contains the cancer type for which the participant is enrolled, and
- Was collected no more than 5 years prior to initiation of therapy, and
- Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
- Contains at least 10% tumor content. 70% tumor content is optimal, and
- No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
-
-
Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment
- Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
- Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
-
Age 13 or older
-
Any sex
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2
-
Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status
-
NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either
- Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
- African American with triple negative (ER-PR-HER2-)
-
NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)
Exclusion Criteria:
-
Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial
- For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
-
Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
-
Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion
-
Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use
-
Factor X inhibitors are permitted
-
Use of anti-platelet drugs are permitted
- Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
-
-
NCI PDMR EXCLUSION CRITERIA: Patients with complete response
-
NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections
-
NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection
- Actively febrile patients with uncertain etiology of febrile episode
- All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
- No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
-
NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Observational (biospecimen collection, chart review)
Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years. |
Undergo CT
Otros nombres:
Undergo MRI
Otros nombres:
Undergo PET/CT
Otros nombres:
Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
Otros nombres:
Medical charts are reviewed and data is collected
Otros nombres:
Undergo paracentesis |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Procure, store and distribute longitudinal biospecimens and associated clinical data
Periodo de tiempo: Up to 10 years
|
Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate. |
Up to 10 years
|
|
Percentage of enrolled patients by cancer type and treatment regimen overall
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of minority and underserved study participants accrued
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of minority and underserved study participants accrued
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Pan-cancer gene panel tumor next generation sequencing test
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling is attempted
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom molecular profiling results are generated
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
|
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Periodo de tiempo: Until completion of biospecimen collection, up to 3 years
|
Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen. |
Until completion of biospecimen collection, up to 3 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Lyndsay N Harris, National Cancer Institute (NCI)
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema endocrino
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades intestinales
- Enfermedades del sistema inmunológico
- Enfermedades de las vías respiratorias
- Neoplasias por tipo histológico
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades Genitales Femeninas
- Enfermedades pulmonares
- Enfermedades hematológicas
- Neoplasias de glándulas endocrinas
- Neoplasias de Cabeza y Cuello
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Enfermedades del Colon
- Enfermedades esofágicas
- Enfermedades Ováricas
- Enfermedades anexiales
- Neoplasias Genitales Femeninas
- Trastornos gonadales
- Enfermedades de la piel
- Enfermedades de los senos
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Leucemia Mieloide
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Tumores neuroendocrinos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Leucemia
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de las trompas de Falopio
- Neoplasias de mama
- Enfermedades de la piel y del tejido conectivo
- Enfermedades hemic y linfáticas
- Neoplasias prostáticas
- Neoplasias de Estómago
- Neoplasias Pulmonares
- Neoplasias colorrectales
- Leucemia Mieloide Aguda
- Neoplasias Esofágicas
- Neoplasias Ováricas
- Carcinoma de pulmón de células no pequeñas
- Mieloma múltiple
- Carcinoma de pulmón de células pequeñas
- Melanoma
- Neoplasias mamarias triple negativas
- Neoplasias de las trompas de Falopio
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Puntas
- Procedimientos quirúrgicos, operativo
- Técnicas de química, analítica
- Análisis de espectro
- Drenaje
- Manejo de muestras
- Espectroscopía de resonancia magnética
- Paracentesis
Otros números de identificación del estudio
Otros números de identificación del estudio
- NCI-2020-00750
- NCI-2020-00750 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- 10323 (Otro identificador: CTEP)
- 10323 (Otro identificador: Division of Cancer Treatment and Diagnosis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .